Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.97 |
| ▸ | TK2 | O00142 | 2/20 | 0.68 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.60 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.60 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.60 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.60 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.56 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.56 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.56 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.52 |
| ▸ | TYMP | P19971 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6758925 | 1.00 | PYGM (0.97) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL19657168 | 1.00 | PYGM (0.97) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL2579064 | 1.00 | PYGM (0.97) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL41201 | 1.00 | PYGM (0.97) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL654693 | 1.00 | PYGM (0.97) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL12143148 | 1.00 | PYGM (0.97) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL158910 | 1.00 | PYGM (0.97) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL15810788 | 1.00 | PYGM (0.97) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| Phosphoric Acid SCHEMBL9804833 | 0.95 | PYGM (0.88) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| Phosphoric Acid SCHEMBL3515238 | 0.95 | PYGM (0.88) | PYGMTK2SLC28A1SLC28A2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2931319-B1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX INC (US) | 2019-08-21 | — | — | EP | disclosed |
| US-8093380-B2 | Viricides, antitumor agents, anticancer agents | PHARMASSET, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8067391-B2 | ODCase inhibitors for the treatment of malaria | UNIVERSITY HEALTH NETWORK (CA) | 2011-11-29 | — | — | US | disclosed |
| US-20100056468-A1 | Pyrimidine Derivatives As Anticancer Agents | UNIVERSITY HEALTH NETWORK (CA) | 2010-03-04 | — | — | US | disclosed |
| US-20090221524-A1 | ODCASE INHIBITORS FOR THE TREATMENT OF MALARIA | UNIVERSITY HEALTH NETWORK (CA) | 2009-09-03 | — | — | US | disclosed |
| EP-1545545-A4 | COMPOUNDS WITH THE BICYCLO 4.2.1 NONANE SYSTEM FOR THE TREATMENT OF i FLAVIVIRIDAE /i INFECTIONS | PHARMASSET INC (US) | 2008-09-03 | — | — | EP | disclosed |
| EP-1545545-A2 | COMPOUNDS WITH THE BICYCLO 4.2.1 NONANE SYSTEM FOR THE TREATMENT OF i FLAVIVIRIDAE /i INFECTIONS | Pharmasset, Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040082574-A1 | Compounds with the bicyclo[4.2.1]nonane system for the treatment of flavivridae infections | PHARMASSET, INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2004013300-A2 | COMPOUNDS WITH THE BICYCLO[4.2.1]NONANE SYSTEM FOR THE TREATMENT OF FLAVIVIRIDAE INFECTIONS | PHARMASSET INC. (US) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221524-A1 | ODCASE INHIBITORS FOR THE TREATMENT OF MALARIA | UMPS, UGDH, UPP1 | PYGM 1863/4885TK2 601/4885SLC28A1 415/4885 |
| US-20040082574-A1 | Compounds with the bicyclo[4.2.1]nonane system for the treatment of flavivridae infections | CYP4B1, HAVCR2, CYP2S1 | PYGM 3617/4885TK2 718/4885SLC28A1 122/4885 |
| US-20100056468-A1 | Pyrimidine Derivatives As Anticancer Agents | DPYD, TYMP, TYMS | PYGM 2807/4885TK2 6/4885SLC28A1 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.